Essential thrombocythaemia

Medical Journal of Australia

Volumn 171, Issue 4, 1999, Pages 210-213

  Bentley, Mark A ^a   Taylor, Kerry McD ^a   Wright, Susan J ^a  

^a MATER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ALPHA INTERFERON; ANAGRELIDE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BUSULFAN; CHLORAMBUCIL; HYDROXYUREA; MELPHALAN; PHOSPHORUS 32; WARFARIN;

ACUTE GRANULOCYTIC LEUKEMIA; CLINICAL FEATURE; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DRUG CONTRAINDICATION; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART FAILURE; HEART PALPITATION; HUMAN; KIDNEY DISEASE; MACROCYTIC ANEMIA; MYELODYSPLASIA; NAIL DISEASE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PREGNANCY; SHORT SURVEY; THROMBOCYTE COUNT; THROMBOCYTHEMIA; ULCER;

EID: 0033575745     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.1999.tb123604.x     Document Type: Short Survey

References (28)

1. Gugliotta L, Marchioli R, Facchini M, et al. Epidemiological, diagnostic, therapeutic and prognostic aspects of essential thrombocythemia in a retrospective study of the GIMMC group in two thousand patients. Blood 1997; 90 Suppl 1: 348a.
2. Murphy S, Peterson P, Hand H, et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29-39.
3. Tefferi A, Ho TC, Ahmann GJ. Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. Am J Med 1994; 97: 374-378.
4. Taylor KM, Shetta M, Talpaz M, et al. Myeloproliferative disorders: usefulness of X-linked probes in diagnosis. Leukemia 1989; 3: 419-422.
5. Kondo T, Okabe M, Sanada M, et al. Familial essential thrombocythemia associated with one-base deletion in the 5′-untranslated region of the thrombopoietin gene. Blood 1998; 4: 1091-1096.
6. Landolfi R, Marchioti R, Pantrono C. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thromb Haemost 1997; 78: 617-621.
7. Tefferi A, Silverstein N, Hoagland HC. Primary thrombocythemia. Semin Oncol 1995; 22: 334-340.
8. Barbui T, Finazzi G. Clinical parameters for determining when and when not to treat essential thrombocythaemia. Semin Hematol 1999; 6 Suppl 2: 14-18.
9. Mesa RA, Tefferi A, Jacobsen SJ, et al. The incidence and epidemiology of essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County study. Blood 1997; 90 Suppl 1: 348a.
10. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukaemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998; 91: 616-622.
11. Murphy S, Iland H, Rosenthal D, Laszio J. Essential thrombocythemia: an interim report from the polycythemia vera study group. Semin Hematol 1986; 23: 177-182.
12. Cortellazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332: 1132-1136.
13. 9/1 be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haem 1998; 100: 15-23.
14. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992; 92: 69-79.
15. Mills AK, Taylor KM, Wright SJ, et al. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia. Aust N Z J Med 1999; 29: 29-35.
16. Bentley M, Taylor K, Grigg A, et al. Long term interferon-alpha 2a does not induce sustained hematologic remission in younger patients with essential thrombocythemia. Leuk Lymph. In press, 1999.
17. Clemens M. Interferons and oncogenes. Nature 1996; 313: 513-532.
18. Milano V, Gabrielli S, Rizzo N, et al. Successful treatment of essential thrombocythemia in a pregnancy with recombinant interferon-α2a. J Maternal Fetal Med 1996; 5: 74-78.
19. Reichel RP, Linkesch W, Schetitska D. Therapy with recombinant interferon alpha-2c during unexpected pregnancy in a patient with chronic myeloid leukaemia. Br J Haem 1992; 82: 472-473.
20. Gisslinger H, Ludwig H, Linkesch W, et al. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet 1989; 1: 634-637.
21. Giles F, Gray A, Brozovic M, et al. Alpha-interferon therapy for essential thrombocythaemia. Lancet 1998; 2: 70-72.
22. Rametta V, Ferrara F, Marattoli V, et al. Recombinant interferon alpha-2b as treatment of essential thrombocythaemia. Acta Haematol 1991; 3: 126-129.
23. Jones GJ, Itri LM. Safety and tolerance of recombinant interferon alpha-2a (Roferon-A) in cancer patients. Cancer 1986; 57 Suppl: 1709-1715.
24. Sacchi S, Gugliotta L, Papineschi F, et al. Alta-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Italian Cooperative Group on ET. Leukemia 1998; 12: 289-294.
25. Cortelazzo S, Marchetti M, Orlando E, et al. Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: role of the lipoxygenase pathway. Am J Hematol 1998; 57: 277-282.
26. Low-dose aspirin in polycythaemia vera: a pilot study. Gruppo Italiano Studio Policitemia (GISP). Br J Haematol 1997; 97: 453-456.
27. van Genderen PJ, Michiels JJ. Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera. Semin Thromb Hem 1997; 23: 357-363.
28. Beressi AH, Tefferi A, Silverstein MN, et al. Outcome analysis of 34 pregnancies in women with essential thrombocythemia. Arch Intern Med 1995; 155: 1217-1222.